Mental Health Blogs

For those of you interested in the stock markets, one of the big stories out there today was that Lilly’s stock dropped about 3 percent today–a sizable move for a fairly stable stock. Reportedly, Lilly CEO John Lechleiter gave a speech before analysts in New York and offered little hope for how the company will fare financially in 2011 and beyond as Zyprexa and, then, Cymbalta come off-patent.

What no one has picked up on in the financial press so far is that Lechleiter also isn’t saying a thing about Lilly’s experimental compound, LY2140023, which failed a major clinical trial earlier this year. The company does have an ongoing safety study of the compound, so they are pushing ahead, but it’s likely Lilly’s revenues will take a huge hit in 2011. Unless the company has some trick up its sleeve. And it usually does.

Go to Source

Related posts:

1. Forest Labs Bullish On Experimental Antipsychotic
2. Lilly Settles Mississippi Zyprexa Claims For $18.5 Million
3. Lilly Details $22 Million In Payouts To Doctor Consultants
4. Pristiq, Soon To Be For Menopausal Women?
5. Lilly Settles Zyprexa Claims With South Carolina